|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sun TY, Xie HJ, Li Z and Kong LF:
Expression of FOXC2 in renal cell carcinoma and its relationship to
clinical pathological features. Int J Clin Exp Med. 8:13388–13392.
2015.PubMed/NCBI
|
|
3
|
Cairns P: Renal cell carcinoma. Cancer
Biomark. 9:461–473. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tostain J, Li G, Gentil-Perret A and
Gigante M: Carbonic anhydrase 9 in clear cell renal cell carcinoma:
A marker for diagnosis, prognosis and treatment. Eur J Cancer.
46:3141–3148. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iwamoto H, Kanda Y, Sejima T, Osaki M,
Okada F and Takenaka A: Serum miR-210 as a potential biomarker of
early clear cell renal cell carcinoma. Int J Oncol. 44:53–58.
2014.PubMed/NCBI
|
|
6
|
Wang X, Wang J, Ma H, Zhang J and Zhou X:
Downregulation of miR-195 correlates with lymph node metastasis and
poor prognosis in colorectal cancer. Med Oncol. 29:919–927. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ujifuku K, Mitsutake N, Takakura S,
Matsuse M, Saenko V, Suzuki K, Hayashi K, Matsuo T, Kamada K,
Nagata I and Yamashita S: miR-195, miR-455-3p and miR-10a(*) are
implicated in acquired temozolomide resistance in glioblastoma
multiforme cells. Cancer Lett. 296:241–248. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang
Y, Zou C, Zhang X, Liu S, Wang X, et al: Analysis of MiR-195 and
MiR-497 expression, regulation and role in breast cancer. Clin
Cancer Res. 17:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP and
Zhuang SM: MicroRNA-195 suppresses tumorigenicity and regulates
G1/S transition of human hepatocellular carcinoma cells.
Hepatology. 50:113–121. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fu MG, Li S, Yu TT, Qian LJ, Cao RS, Zhu
H, Xiao B, Jiao CH, Tang NN, Ma JJ, et al: Differential expression
of miR-195 in esophageal squamous cell carcinoma and miR-195
expression inhibits tumor cell proliferation and invasion by
targeting of Cdc42. FEBS Lett. 587:3471–3479. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fei X, Qi M, Wu B, Song Y, Wang Y and Li
T: MicroRNA-195-5p suppresses glucose uptake and proliferation of
human bladder cancer T24 cells by regulating GLUT3 expression. FEBS
Lett. 586:392–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao C, Qi L, Chen M, Liu L, Yan W, Tong S
and Zu X: microRNA-195 inhibits cell proliferation in bladder
cancer via inhibition of cell division control protein 42
homolog/signal transducer and activator of transcription-3
signaling. Exp Ther Med. 10:1103–1108. 2015.PubMed/NCBI
|
|
13
|
Mao JH, Zhou RP, Peng AF, Liu ZL, Huang
SH, Long XH and Shu Y: microRNA-195 suppresses osteosarcoma cell
invasion and migration in vitro by targeting FASN. Oncol Lett.
4:1125–1129. 2012.PubMed/NCBI
|
|
14
|
Li Z, Wang H, Wang Z and Cai H: MiR-195
inhibits the proliferation of human cervical cancer cells by
directly targeting cyclin D1. Tumour Biol. 37:6457–6463. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yi Z, Fu Y, Zhao S, Zhang X and Ma C:
Differential expression of miRNA patterns in renal cell carcinoma
and nontumorous tissues. J Cancer Res Clin Oncol. 136:855–862.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2 (−Delta Delta C (T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu L, Chen L, Xu Y, Li R and Du X:
microRNA-195 promotes apoptosis and suppresses tumorigenicity of
human colorectal cancer cells. Biochem Biophys Res Commun.
400:236–240. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang QQ, Xu H, Huang MB, Ma LM, Huang QJ,
Yao Q, Zhou H and Qu LH: MicroRNA-195 plays a tumor-suppressor role
in human glioblastoma cells by targeting signaling pathways
involved in cellular proliferation and invasion. Neuro Oncol.
14:278–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Deng H, Guo Y, Song H, Xiao B, Sun W, Liu
Z, Yu X, Xia T, Cui L and Guo J: MicroRNA-195 and microRNA-378
mediate tumor growth suppression by epigenetical regulation in
gastric cancer. Gene. 518:351–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang R, Zhao N, Li S, Fang JH, Chen MX,
Yang J, Jia WH, Yuan Y and Zhuang SM: MicroRNA-195 suppresses
angiogenesis and metastasis of hepatocellular carcinoma by
inhibiting the expression of VEGF, VAV2 and CDC42. Hepatology.
58:642–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Luo Q, Wei C, Li X, Li J, Chen L, Huang Y,
Song H, Li D and Fang L: MicroRNA-195-5p is a potential diagnostic
and therapeutic target for breast cancer. Oncol Rep. 31:1096–1102.
2014.PubMed/NCBI
|
|
22
|
Yongchun Z, Linwei T, Xicai W, Lianhua Y,
Guangqiang Z, Ming Y, Guanjian L, Yujie L and Yunchao H:
MicroRNA-195 inhibits non-small cell lung cancer cell
proliferation, migration and invasion by targeting MYB. Cancer
Lett. 347:65–74. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cai C, Chen QB, Han ZD, Zhang YQ, He HC,
Chen JH, Chen YR, Yang SB, Wu YD, Zeng YR, et al: miR-195 Inhibits
tumor progression by targeting RPS6KB1 in human prostate cancer.
Clin Cancer Res. 21:4922–4934. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo J, Wang M and Liu X: MicroRNA-195
suppresses tumor cell proliferation and metastasis by directly
targeting BCOX1 in prostate carcinoma. J Exp Clin Cancer Res.
34:912015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu J, Ji A, Wang X, Zhu Y, Yu Y, Lin Y,
Liu Y, Li S, Liang Z, Xu X, et al: MicroRNA-195-5p, a new regulator
of Fra-1, suppresses the migration and invasion of prostate cancer
cells. J Transl Med. 13:2892015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu C, Guan H, Wang Y, Chen M, Xu B, Zhang
L, Lu K, Tao T, Zhang X and Huang Y: miR-195 inhibits EMT by
targeting FGF2 in prostate cancer cells. PLoS One. 10:e01440732015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin Y, Wu J, Chen H, Mao Y, Liu Y, Mao Q,
Yang K, Zheng X and Xie L: Cyclin-dependent kinase 4 is a novel
target in micoRNA-195-mediated cell cycle arrest in bladder cancer
cells. FEBS Lett. 586:442–447. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang X, Yu J, Yin J, Xiang Q, Tang H and
Lei X: MiR-195 regulates cell apoptosis of human hepatocellular
carcinoma cells by targeting LATS2. Pharmazie. 67:645–651.
2012.PubMed/NCBI
|
|
29
|
Jiang HL, Yu H, Ma X, Xu D, Lin GF, Ma DY
and Jin JZ: MicroRNA-195 regulates steroid receptor coactivator-3
protein expression in hepatocellular carcinoma cells. Tumour Biol.
35:6955–6960. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zheng C, Li J, Wang Q, Liu W, Zhou J, Liu
R, Zeng Q, Peng X, Huang C, Cao P, et al: MicroRNA-195 functions as
a tumor suppressor by inhibiting CBX4 in hepatocellular carcinoma.
Oncol Rep. 33:1115–1122. 2015.PubMed/NCBI
|
|
31
|
Ding J, Huang S, Wang Y, Tian Q, Zha R,
Shi H, Wang Q, Ge C, Chen T, Zhao Y, et al: Genome-wide screening
reveals that miR-195 targets the TNF-α/NF-κB pathway by
down-regulating IkappaB kinase alpha and TAB3 in hepatocellular
carcinoma. Hepatology. 58:654–666. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Amer M, Elhefnawi M, El-Ahwany E, Awad AF,
Gawad NA, Zada S and Tawab FM: Hsa-miR-195 targets PCMT1 in
hepatocellular carcinoma that increases tumor life span. Tumour
Biol. 35:11301–11309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Furuta M, Kozaki K, Tanimoto K, Tanaka S,
Arii S, Shimamura T, Niida A, Miyano S and Inazawa J: The
tumor-suppressive miR-497-195 cluster targets multiple cell-cycle
regulators in hepatocellular carcinoma. PLoS One. 8:e601552013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang B, Tan Z and Song Y: Study on the
molecular regulatory mechanism of MicroRNA-195 in the invasion and
metastasis of colorectal carcinoma. Int J Clin Exp Med.
8:3793–3800. 2015.PubMed/NCBI
|
|
35
|
Wang L, Qian L, Li X and Yan J:
MicroRNA-195 inhibits colorectal cancer cell proliferation,
colony-formation and invasion through targeting CARMA3. Mol Med
Rep. 10:473–478. 2014.PubMed/NCBI
|
|
36
|
Tashkandi H, Shah N, Patel Y and Chen H:
Identification of new miRNA biomarkers associated with
HER2-positive breast cancers. Oncoscience. 2:924–929.
2015.PubMed/NCBI
|
|
37
|
Zhang Y, Zhang D, Wang F, Xu D, Guo Y and
Cui W: Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497)
as novel non-invasive biomarkers for detection of cervical cancer.
Sci Rep. 5:179422015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao FL, Dou YC, Wang XF, Han DC, Lv ZG,
Ge SL and Zhang YK: Serum microRNA-195 is down-regulated in breast
cancer: A potential marker for the diagnosis of breast cancer. Mol
Biol Rep. 41:5913–5922. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cai H, Zhao H, Tang J and Wu H: Serum
miR-195 is a diagnostic and prognostic marker for osteosarcoma. J
Surg Res. 194:505–510. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Soon PS, Tacon LJ, Gill AJ, Bambach CP,
Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson
BG and Sidhu SB: miR-195 and miR-483-5p identified as predictors of
poor prognosis in adrenocortical cancer. Clin Cancer Res.
15:7684–7692. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang X, Yin J, Yu J, Xiang Q, Liu Y, Tang
S, Liao D, Zhu B, Zu X, Tang H and Lei X: miRNA-195 sensitizes
human hepatocellular carcinoma cells to 5-FU by targeting BCL-w.
Oncol Rep. 27:250–257. 2012.PubMed/NCBI
|
|
42
|
Qu J, Zhao L, Zhang P, Wang J, Xu N, Mi W,
Jiang X, Zhang C and Qu J: MicroRNA-195 chemosensitizes colon
cancer cells to the chemotherapeutic drug doxorubicin by targeting
the first binding site of BCL2L2 mRNA. J Cell Physiol. 230:535–545.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang G, Wu D, Zhu J, Jiang O, Shi Q, Tian
J and Weng Y: Upregulation of miR-195 increases the sensitivity of
breast cancer cells to Adriamycin treatment through inhibition of
Raf-1. Oncol Rep. 30:877–889. 2013.PubMed/NCBI
|
|
44
|
Zhu J, Ye Q, Chang L, Xiong W, He Q and Li
W: Upregulation of miR-195 enhances the radiosensitivity of breast
cancer cells through the inhibition of BCL-2. Int J Clin Exp Med.
8:9142–9148. 2015.PubMed/NCBI
|
